AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Abstract

AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).

Keywords

T790MMedicineLung cancerEpidermal growth factor receptorEGFR inhibitorsCancer researchTyrosine-kinase inhibitorMutationTyrosine kinaseDrug resistanceResistance mutationGefitinibCancerOncologyReceptorInternal medicineBiologyGeneGeneticsPolymerase chain reaction

MeSH Terms

AcrylamidesAdultAgedAged80 and overAniline CompoundsAntineoplastic AgentsCarcinomaNon-Small-Cell LungDisease-Free SurvivalDose-Response RelationshipDrugDrug ResistanceNeoplasmErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationProtein Kinase Inhibitors

Affiliated Institutions

Related Publications

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

James Bean , Gregory J. Riely , Marissa N. Balak +4 more

Abstract Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to ...

2008 Clinical Cancer Research 276 citations

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

Lecia V. Sequist , Renato Martins , David R. Spigel +16 more

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR ...

2008 Journal of Clinical Oncology 829 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao , Vincent A. Miller , Maureen F. Zakowski +12 more

Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib ...

2004 Proceedings of the National Academy o... 4316 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch , Daphne W. Bell , Raffaella Sordella +11 more

A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor ge...

2004 New England Journal of Medicine 11361 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez , Pasi A. Jänne , Jeffrey C. Lee +14 more

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGF...

2004 Science 9327 citations

Publication Info

Year: 2015
Type: article
Volume: 372
Issue: 18
Pages: 1689-1699
Citations: 2069
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2069

OpenAlex

114

Influential

1692

CrossRef

Cite This

APA Style

                            
                                
                                    Pasi A. Jänne, 
                                
                                    James Chih‐Hsin Yang, 
                                
                                    Dong‐Wan Kim
                                
                                et al.
                            
                            (2015). 
                            AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. 
                            New England Journal of Medicine
                            , 372
                            (18)
                            , 1689-1699.
                            https://doi.org/10.1056/nejmoa1411817
                        

Identifiers

DOI: 10.1056/nejmoa1411817
PMID: 25923549

Data Quality

Data completeness: 86%

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Abstract

Keywords

MeSH Terms

Affiliated Institutions

Related Publications

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Publication Info

External Links

Social Impact

Citation Metrics

Cite This

Identifiers

Data Quality